Loading...
Loading...
GMAB| Name | Value |
|---|---|
| Revenues | 5,402.0M |
| Cost of Revenue | 190.0M |
| Gross Profit | 5,212.0M |
| Operating Expense | 3,396.0M |
| Operating I/L | 1,816.0M |
| Other Income/Expense | 311.0M |
| Interest Income | 292.0M |
| Pretax | 2,127.0M |
| Income Tax Expense | 719.0M |
| Net Income/Loss | 1,408.0M |
Genmab A/S is a biotechnology company specializing in the development of antibody therapeutics for the treatment of cancer and other diseases. The company's primary revenue comes from the commercialization of its products, including DARZALEX for multiple myeloma, teprotumumab for thyroid eye disease, ofatumurnab for chronic lymphocytic leukemia and multiple sclerosis, and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Genmab A/S also generates income from its collaboration agreements with other biotech and pharmaceutical companies for the research and development of various antibody products, as well as from its approximately 20 active pre-clinical programs.
